Gennex Laboratories Ltd vs Morepen Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 11, 2026

Key Highlights

The Latest Trading Price of Gennex Laboratories Ltd is ₹ 9.94 as of 11 May 16:01 . The P/E Ratio of Gennex Laboratories Ltd changed from 12.2 on March 2021 to 15.1 on March 2025 . This represents a CAGR of 4.36% over 5 yearsThe P/E Ratio of Morepen Laboratories Ltd changed from 14.9 on March 2021 to 22.3 on March 2025 . This represents a CAGR of 8.40% over 5 years The Market Cap of Gennex Laboratories Ltd changed from ₹ 49.46 crore on March 2021 to ₹ 274.07 crore on March 2025 . This represents a CAGR of 40.84% over 5 yearsThe Market Cap of Morepen Laboratories Ltd changed from ₹ 1446 crore on March 2021 to ₹ 2621 crore on March 2025 . This represents a CAGR of 12.64% over 5 years The revenue of Gennex Laboratories Ltd for the Dec '25 is ₹ 42.96 crore as compare to the Sep '25 revenue of ₹ 39.3 crore. This represent the growth of 9.31% The revenue of Morepen Laboratories Ltd for the Dec '25 is ₹ 487.97 crore as compare to the Sep '25 revenue of ₹ 442.04 crore. This represent the growth of 10.39% The ebitda of Gennex Laboratories Ltd for the Dec '25 is ₹ 8.27 crore as compare to the Sep '25 ebitda of ₹ 7.56 crore. This represent the growth of 9.39% The ebitda of Morepen Laboratories Ltd for the Dec '25 is ₹ 50.12 crore as compare to the Sep '25 ebitda of ₹ 61.16 crore. This represent the decline of -18.05% The net profit of Gennex Laboratories Ltd changed from ₹ 4.66 crore to ₹ 5.99 crore over 7 quarters. This represents a CAGR of 15.43% The net profit of Morepen Laboratories Ltd changed from ₹ 36.17 crore to ₹ 27.5 crore over 7 quarters. This represents a CAGR of -14.50% The Dividend Payout of Gennex Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Morepen Laboratories Ltd changed from 10.79 % on March 2025 to 10.79 % on March 2025 . This represents a CAGR of 0.00% over 1 years .

About Gennex Laboratories Ltd

Gennex Laboratories Limited, formerly known as Prudential Pharmaceuticals Limited was incorporated on June 25, 1985.
The Company got converted into a Public Limited Company and the name was changed from Prudential Pharmaceuticals Limited to Gennex Laboratories Limited in 2007. The Company is in the business of Manufacturing of Bulk Drugs, Intermediates and Biotech Products.
The Company has over the years added more capacity and infrastructure by way of an additional production block and equipment to the plant to handle more products and tonnages.
The Company is having a professionally managed team at every stage of its operations. Apart from these, Gennex is among the leading Vertically Integrated' pharmaceutical companies in India and has a robust product portfolio spread over major product segments encompassing Expectorants, Muscle Relaxants, Analgesic and Anti Fungal.

About Morepen Laboratories Ltd

Morepen Laboratories Limited is an India-based pharmaceutical company.
Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.

FAQs for the comparison of Gennex Laboratories Ltd and Morepen Laboratories Ltd

Which company has a larger market capitalization, Gennex Laboratories Ltd or Morepen Laboratories Ltd?

Market cap of Gennex Laboratories Ltd is 242 Cr while Market cap of Morepen Laboratories Ltd is 2,503 Cr

What are the key factors driving the stock performance of Gennex Laboratories Ltd and Morepen Laboratories Ltd?

The stock performance of Gennex Laboratories Ltd and Morepen Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gennex Laboratories Ltd and Morepen Laboratories Ltd?

As of May 11, 2026, the Gennex Laboratories Ltd stock price is INR ₹10.0. On the other hand, Morepen Laboratories Ltd stock price is INR ₹45.69.

How do dividend payouts of Gennex Laboratories Ltd and Morepen Laboratories Ltd compare?

To compare the dividend payouts of Gennex Laboratories Ltd and Morepen Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.